Criteria

WHO criteria (1999)[77]

Insulin resistance is defined as:

  • Type 2 diabetes mellitus (DM) (i.e., fasting plasma glucose ≥7 mmol/L [≥126 mg/dL], or 2-hour postglucose load [oral glucose tolerance test] ≥11.1 mmol/L [ ≥200 mg/dL]), or

  • Impaired fasting glucose (i.e., ≥5.6 mmol/L [>100 mg/dL]), or

  • Impaired glucose tolerance (i.e., glucose <11.1 mmol/L [<200 mg/dL] and ≥7.8 mmol/L [>140 mg/dL] after oral glucose tolerance test), or

  • For those with normal fasting glucose levels, glucose uptake below the lowest quartile for the background population under hyperinsulinaemic and euglycaemic conditions is used.

Plus two of the following:

  • Abdominal obesity (waist-to-hip ratio >0.9 in men or >0.85 in women, or BMI >30 kg/m²)

  • Triglycerides ≥1.7 mmol/L (≥150 mg/dL), and/or HDL-cholesterol <40 mg/dL (<1.04 mmol/L) in men and <50 mg/dL (<1.29 mmol/L) in women

  • BP ≥140/90 mmHg

  • Increased urinary albumin excretion (urinary albumin secretion rate ≥20 micrograms/minute or albumin-to-creatinine ratio ≥30 mg/g).

European Group for the Study of Insulin Resistance criteria (1999)[78]

Plasma insulin above the 75th percentile of non-diabetic patients plus two of the following lead to a diagnosis of metabolic syndrome:

  • Waist circumference 94 cm (37 inches) or greater in men, 80 cm (31 inches) or greater in women

  • Triglycerides ≥1.7 mmol/L (≥150 mg/dL) and/or HDL-cholesterol <1.01 mmol/L (<39 mg/dL) in men or women

  • BP ≥140/90 mmHg or taking antihypertensive drugs

  • Fasting glucose ≥6.1 mmol/L (≥110 mg/dL).

National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III) criteria (2001)[3]

Any three of the following lead to a diagnosis of metabolic syndrome:

  • Waist circumference >102 cm (40 inches) in men, >88 cm (35 inches) in women

  • Triglycerides ≥150 mg/dL (≥1.7 mmol/L)

  • HDL-cholesterol <1.04 mmol/L (<40 mg/dL) in men and <1.29 mmol/L (<50 mg/dL) in women

  • BP ≥130/85 mmHg

  • Fasting glucose 6.1 mmol/L (≥110 mg/dL).

American Association of Clinical Endocrinology criteria (2003)[79]

Impaired glucose tolerance or impaired fasting glucose plus any of the following based on clinical judgement lead to a diagnosis of metabolic syndrome:

  • BMI ≥25 kg/m²

  • Triglycerides ≥1.7 mmol/L (≥150 mg/dL) and/or HDL-cholesterol <1.04 mmol/L (<40 mg/dL) in men and <1.29 mmol/L (<50 mg/dL) in women

  • BP ≥130/85 mmHg.

International Diabetes Federation (IDF) criteria (2005)[80]

Central obesity (defined as waist circumference but can be assumed if BMI >30 kg/m²) with ethnicity-specific values* plus two of the following lead to a diagnosis of metabolic syndrome:

  • Triglycerides ≥1.7 mmol/L (≥150 mg/dL)

  • HDL-cholesterol <1.04 mmol/L (<40 mg/dL) in men and <1.29 mmol/L (<50 mg/dL) in women

  • BP ≥130/85 mmHg

  • Fasting glucose ≥5.6 mmol/L (≥100 mg/dL).

*To meet the criteria, waist circumference must be: for Europeans, >94 cm (>37 inches) in men and >80 cm (>31 inches) in women; and for South Asians, Chinese, and Japanese, >90 cm (>35 inches) in men and >80 cm (>31 inches) in women. For ethnic South and Central Americans, South Asian data are used, and for sub-Saharan Africans and Eastern Mediterranean and Middle East (Arab) populations, European data are used.

American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) criteria (2005)[81]

Any three of the following lead to a diagnosis of metabolic syndrome:

  • Waist circumference ≥102 cm (≥40 inches) in men, ≥88 cm (≥35 inches) in women

  • Triglycerides ≥1.7 mmol/L (≥150 mg/dL)

  • HDL-cholesterol <1.04 mmol/L (<40 mg/dL) in men and <1.29 mmol/L (<50 mg/dL) in women

  • BP ≥130/85 mmHg

  • Fasting glucose ≥5.6 mmol/L (≥100 mg/dL).

Consensus definition (incorporating IDF and AHA/NHLBI definitions)[1]

Any three of the following lead to a diagnosis of metabolic syndrome:

  • Elevated waist circumference (population- and country-specific definitions)

  • Triglycerides ≥1.7 mmol/L (≥150 mg/dL)

  • HDL-cholesterol <1.04 mmol/L (<40 mg/dL) in men and <1.29 mmol/L (<50 mg/dL) in women

  • BP ≥130/85 mmHg

  • Fasting glucose ≥5.6 mmol/L (≥100 mg/dL).

It is recommended that the IDF cut points be used for non-Europeans and either the IDF or AHA/NHLBI cut points used for people of European origin until more data are available.

Use of this content is subject to our disclaimer